Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
An (1) existing share (regardless of share class) entitles to five (5) subscription rights and two (2) subscription rights give the right to subscribe for one (1) new share of series B.
Updated assessment of Net Asset Value in Karolinska Development
The official NAV discount at a price of 0.335 SEK is approx. 92 % (ibindex.se). After a fully subscribed issue, it will fall to approx. 77 % at an expected price of 0.30 SEK.
(Briefly, the price can of course be lower right after the issue, as is unfortunately often seen when the guarantors sell off the new shares they have bought at a large discount compared to us other shareholders.)
I am, however, more interested in what I call the real NAV discount.
I assume that the share price is 0.30 SEK, that the issue is fully subscribed and adds 203 million SEK minus 17 million SEK in costs.
Under these assumptions, the buyers of the newly issued shares get the entire holding of unlisted shares quite free – or almost free. More precisely, the real NAV discount under these assumptions becomes 99 %.
I calculate the real NAV discount solely in relation to the unlisted shares, by first fully offsetting the value of the listed shares (there is only a very small listed share left currently) as well as positive capital including receivables (and offsets any debt.)
After that, it is of course necessary to look at what unlisted shares are in the company's portfolio.
Firstly, one must consider whether the value of the unlisted shares is correctly determined. I do not have the prerequisites to know that, and must therefore assess whether I find the management trustworthy and competent, including to what extent the management itself invests, and whether there are larger investors who sometimes supplement further.
But now that the entire pool of unlisted shares is free, much uncertainty can be priced in.
Secondly, one must consider the security in relation to how much individual shares make up in the portfolio. In this share, Umecrine alone accounts for almost 55 % of the unlisted shares, which some believe is the reason for the large NAV discount in this company. But the large NAV discount more than sufficiently accounts for if Umecrine, contrary to expectations, should be worth 0 kr. So that does not worry me. Even if all 3 largest companies were to go bankrupt, the share's NAV would still be intact in relation to the price.
I choose, as I usually do with this type of issue, to sell all shares (almost) in the company, even if it is loss-making, and use the money to buy new ones in the issue. This way I support the issue and contribute to fewer shares being sold to guarantors with further discount and dilution of other shareholders.
KDEV is absolutely ridiculously priced at the moment. It trades at half the tax value of the accumulated losses. In other words, a profitable buyer who can utilize the losses will get all other net assets for free plus a good deal on top.
They exist partly as Invox Pharma and partly as Worldwide International Investments. I think it's the same owner behind them. Does anyone have other information?
Is there any possibility that the General Meeting of Shareholders will reject this very dilutive share issue? We will soon be trading below the issue price!
Yes, why doesn't the main owner make a commitment corresponding to their share? They dominate the board, so it's surely not a question of the issue not being anchored with the largest owner? Is it 1. because they don't want/can't invest another 100M here and the market will soon be flooded with subscription rights, or is it 2. because they want to invest even more and hope for a low subscription rate so they can increase their stake at a cheap price? Should that then trigger a mandatory bid? If it's alternative 1, then there's surely the possibility that a new larger owner will come in who can take over power and carry out a slaughter and carve-out process to extract the net asset value?
Very relevant consideration. Unfortunately, I have the same thoughts both here and especially in First Ventures' emission. In that light, I see no other option than to participate in the emission.
Ner, ner, ner, ner..new issue, after new issue and the poor small shareholders lose and lose......
Näytä enemmän
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Uutiset ja lehdistötiedotteet
Analyysit
eilen klo 12.05
∙
Lehdistötiedote
Karolinska Development's portfolio company Modus Therapeutics initiates dosing in phase 2a study in patients with chronic kidney disease with anemia
eilen klo 12.05
∙
Lehdistötiedote
Karolinska Developments portföljbolag Modus Therapeutics inleder doseringen i en klinisk fas 2a-studie i patienter med kronisk njursjukdom med anemi
eilen klo 08.25
∙
Lehdistötiedote
DNB Carnegie Access: Karolinska Development: Positive study data from AnaCardio
eilen klo 07.22
∙
Osakeuutinen
FLERIE AB: ANACARDIO SER GYNNSAM SÄKERHET, TOLERABILITET I FAS 2A
eilen klo 07.12
∙
Osakeuutinen
Fleries portföljbolag Anacardio rapporterar starka studieresultat för AC01 i patienter med hjärtsvikt
eilen klo 07.00
∙
Lehdistötiedote
Karolinska Developments portföljbolag AnaCardio presenterar positiva top line-resultat från fas 2a-studien med läkemedelskandidaten AC01
eilen klo 07.00
∙
Lehdistötiedote
Karolinska Development’s portfolio company AnaCardio presents positive top-line data from the phase 2a study of its drug candidate AC01
2 joulu 09.23
∙
Lehdistötiedote
Aktieägarna i Karolinska Development AB (publ) kallas till extra bolagsstämma
2 joulu 09.23
∙
Lehdistötiedote
Notice of Extraordinary General Meeting in Karolinska Development AB (publ)
1 joulu 16.35
∙
Markkinakommentti
BÖRSEN: SAAB BACKADE MEDAN H&M STEG, OMXS30 -0,1%
1 joulu 12.24
∙
Markkinakommentti
BÖRSEN: SAAB TAPPAR, UPPGÅNG FÖR BOLIDEN, OMXS30 -0,6%
1 joulu 10.25
∙
Lehdistötiedote
DNB Carnegie Access: Karolinska Development: Aims to strengthen its balance shee
1 joulu 08.49
∙
Markkinakommentti
BÖRSEN: NED MED OMVÄRLDEN, BANKER MOT STRÖMMEN, OMXS30 -0,2%
1 joulu 08.33
∙
Osakeuutinen
Stockholm Bullets - VEF stiger efter största innehavet Creditas satt omsättningsrekord
1 joulu 07.35
∙
Markkinakommentti
BÖRSEN: VÄNTAS ÖPPNA NEDÅT I LINJE MED OMVÄRLDEN
1 joulu 07.13
∙
Osakeuutinen
Karolinska Development föreslår nyemission på 203 miljoner kronor samt namnbyte
1 joulu 07.03
∙
Osakeuutinen
KAROLINSKA DEVELOPMENT: FÖRETRÄDESEMISSION 203 MLN KR
1 joulu 07.00
∙
Lehdistötiedote
Karolinska Development AB (publ) announces a rights issue of up to approximately SEK 203 million, subject to subsequent approval by the Extraordinary General Meeting, and proposes change of company name to KDventures AB
1 joulu 07.00
∙
Lehdistötiedote
Karolinska Development AB (publ) offentliggör företrädesemission om upp till cirka 203 MSEK, villkorat av bolagsstämmans efterföljande godkännande samt föreslår namnbyte till KDventures AB
17 marras 14.14
∙
Osakeuutinen
DNB Carnegie sänker motiverat värde på Karolinska Development till 1,4-2,1 kronor per aktie
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Sertifikaatit
2025 Q3 -tulosraportti
Vain PDF
27 päivää sitten
Uutiset ja analyysit
Uutiset ja lehdistötiedotteet
Analyysit
eilen klo 12.05
∙
Lehdistötiedote
Karolinska Development's portfolio company Modus Therapeutics initiates dosing in phase 2a study in patients with chronic kidney disease with anemia
eilen klo 12.05
∙
Lehdistötiedote
Karolinska Developments portföljbolag Modus Therapeutics inleder doseringen i en klinisk fas 2a-studie i patienter med kronisk njursjukdom med anemi
eilen klo 08.25
∙
Lehdistötiedote
DNB Carnegie Access: Karolinska Development: Positive study data from AnaCardio
eilen klo 07.22
∙
Osakeuutinen
FLERIE AB: ANACARDIO SER GYNNSAM SÄKERHET, TOLERABILITET I FAS 2A
eilen klo 07.12
∙
Osakeuutinen
Fleries portföljbolag Anacardio rapporterar starka studieresultat för AC01 i patienter med hjärtsvikt
eilen klo 07.00
∙
Lehdistötiedote
Karolinska Developments portföljbolag AnaCardio presenterar positiva top line-resultat från fas 2a-studien med läkemedelskandidaten AC01
eilen klo 07.00
∙
Lehdistötiedote
Karolinska Development’s portfolio company AnaCardio presents positive top-line data from the phase 2a study of its drug candidate AC01
2 joulu 09.23
∙
Lehdistötiedote
Aktieägarna i Karolinska Development AB (publ) kallas till extra bolagsstämma
2 joulu 09.23
∙
Lehdistötiedote
Notice of Extraordinary General Meeting in Karolinska Development AB (publ)
1 joulu 16.35
∙
Markkinakommentti
BÖRSEN: SAAB BACKADE MEDAN H&M STEG, OMXS30 -0,1%
1 joulu 12.24
∙
Markkinakommentti
BÖRSEN: SAAB TAPPAR, UPPGÅNG FÖR BOLIDEN, OMXS30 -0,6%
1 joulu 10.25
∙
Lehdistötiedote
DNB Carnegie Access: Karolinska Development: Aims to strengthen its balance shee
1 joulu 08.49
∙
Markkinakommentti
BÖRSEN: NED MED OMVÄRLDEN, BANKER MOT STRÖMMEN, OMXS30 -0,2%
1 joulu 08.33
∙
Osakeuutinen
Stockholm Bullets - VEF stiger efter största innehavet Creditas satt omsättningsrekord
1 joulu 07.35
∙
Markkinakommentti
BÖRSEN: VÄNTAS ÖPPNA NEDÅT I LINJE MED OMVÄRLDEN
1 joulu 07.13
∙
Osakeuutinen
Karolinska Development föreslår nyemission på 203 miljoner kronor samt namnbyte
1 joulu 07.03
∙
Osakeuutinen
KAROLINSKA DEVELOPMENT: FÖRETRÄDESEMISSION 203 MLN KR
1 joulu 07.00
∙
Lehdistötiedote
Karolinska Development AB (publ) announces a rights issue of up to approximately SEK 203 million, subject to subsequent approval by the Extraordinary General Meeting, and proposes change of company name to KDventures AB
1 joulu 07.00
∙
Lehdistötiedote
Karolinska Development AB (publ) offentliggör företrädesemission om upp till cirka 203 MSEK, villkorat av bolagsstämmans efterföljande godkännande samt föreslår namnbyte till KDventures AB
17 marras 14.14
∙
Osakeuutinen
DNB Carnegie sänker motiverat värde på Karolinska Development till 1,4-2,1 kronor per aktie
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
An (1) existing share (regardless of share class) entitles to five (5) subscription rights and two (2) subscription rights give the right to subscribe for one (1) new share of series B.
Updated assessment of Net Asset Value in Karolinska Development
The official NAV discount at a price of 0.335 SEK is approx. 92 % (ibindex.se). After a fully subscribed issue, it will fall to approx. 77 % at an expected price of 0.30 SEK.
(Briefly, the price can of course be lower right after the issue, as is unfortunately often seen when the guarantors sell off the new shares they have bought at a large discount compared to us other shareholders.)
I am, however, more interested in what I call the real NAV discount.
I assume that the share price is 0.30 SEK, that the issue is fully subscribed and adds 203 million SEK minus 17 million SEK in costs.
Under these assumptions, the buyers of the newly issued shares get the entire holding of unlisted shares quite free – or almost free. More precisely, the real NAV discount under these assumptions becomes 99 %.
I calculate the real NAV discount solely in relation to the unlisted shares, by first fully offsetting the value of the listed shares (there is only a very small listed share left currently) as well as positive capital including receivables (and offsets any debt.)
After that, it is of course necessary to look at what unlisted shares are in the company's portfolio.
Firstly, one must consider whether the value of the unlisted shares is correctly determined. I do not have the prerequisites to know that, and must therefore assess whether I find the management trustworthy and competent, including to what extent the management itself invests, and whether there are larger investors who sometimes supplement further.
But now that the entire pool of unlisted shares is free, much uncertainty can be priced in.
Secondly, one must consider the security in relation to how much individual shares make up in the portfolio. In this share, Umecrine alone accounts for almost 55 % of the unlisted shares, which some believe is the reason for the large NAV discount in this company. But the large NAV discount more than sufficiently accounts for if Umecrine, contrary to expectations, should be worth 0 kr. So that does not worry me. Even if all 3 largest companies were to go bankrupt, the share's NAV would still be intact in relation to the price.
I choose, as I usually do with this type of issue, to sell all shares (almost) in the company, even if it is loss-making, and use the money to buy new ones in the issue. This way I support the issue and contribute to fewer shares being sold to guarantors with further discount and dilution of other shareholders.
KDEV is absolutely ridiculously priced at the moment. It trades at half the tax value of the accumulated losses. In other words, a profitable buyer who can utilize the losses will get all other net assets for free plus a good deal on top.
They exist partly as Invox Pharma and partly as Worldwide International Investments. I think it's the same owner behind them. Does anyone have other information?
Is there any possibility that the General Meeting of Shareholders will reject this very dilutive share issue? We will soon be trading below the issue price!
Yes, why doesn't the main owner make a commitment corresponding to their share? They dominate the board, so it's surely not a question of the issue not being anchored with the largest owner? Is it 1. because they don't want/can't invest another 100M here and the market will soon be flooded with subscription rights, or is it 2. because they want to invest even more and hope for a low subscription rate so they can increase their stake at a cheap price? Should that then trigger a mandatory bid? If it's alternative 1, then there's surely the possibility that a new larger owner will come in who can take over power and carry out a slaughter and carve-out process to extract the net asset value?
Very relevant consideration. Unfortunately, I have the same thoughts both here and especially in First Ventures' emission. In that light, I see no other option than to participate in the emission.
Ner, ner, ner, ner..new issue, after new issue and the poor small shareholders lose and lose......
Näytä enemmän
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
3 500
0,313
Myynti
Määrä
0,318
74 797
Viimeisimmät kaupat
Näytä enemmän
Aika
Hinta
Määrä
Ostaja
Myyjä
0,317
9 560
-
-
0,317
38 292
-
-
0,317
1 487
-
-
0,318
8 490
-
-
0,318
112 343
-
-
Ylin
0,337
VWAP
0,317
Alin
0,312
VaihtoMäärä
0,6 1 981 303
VWAP
0,317
Ylin
0,337
Alin
0,312
VaihtoMäärä
0,6 1 981 303
Tietoa osakekaupankäyntiin liittyvistä riskeistä
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Karolinska Development's portfolio company Modus Therapeutics initiates dosing in phase 2a study in patients with chronic kidney disease with anemia
eilen klo 12.05
∙
Lehdistötiedote
Karolinska Developments portföljbolag Modus Therapeutics inleder doseringen i en klinisk fas 2a-studie i patienter med kronisk njursjukdom med anemi
eilen klo 08.25
∙
Lehdistötiedote
DNB Carnegie Access: Karolinska Development: Positive study data from AnaCardio
eilen klo 07.22
∙
Osakeuutinen
FLERIE AB: ANACARDIO SER GYNNSAM SÄKERHET, TOLERABILITET I FAS 2A
eilen klo 07.12
∙
Osakeuutinen
Fleries portföljbolag Anacardio rapporterar starka studieresultat för AC01 i patienter med hjärtsvikt
eilen klo 07.00
∙
Lehdistötiedote
Karolinska Developments portföljbolag AnaCardio presenterar positiva top line-resultat från fas 2a-studien med läkemedelskandidaten AC01
eilen klo 07.00
∙
Lehdistötiedote
Karolinska Development’s portfolio company AnaCardio presents positive top-line data from the phase 2a study of its drug candidate AC01
2 joulu 09.23
∙
Lehdistötiedote
Aktieägarna i Karolinska Development AB (publ) kallas till extra bolagsstämma
2 joulu 09.23
∙
Lehdistötiedote
Notice of Extraordinary General Meeting in Karolinska Development AB (publ)
1 joulu 16.35
∙
Markkinakommentti
BÖRSEN: SAAB BACKADE MEDAN H&M STEG, OMXS30 -0,1%
1 joulu 12.24
∙
Markkinakommentti
BÖRSEN: SAAB TAPPAR, UPPGÅNG FÖR BOLIDEN, OMXS30 -0,6%
1 joulu 10.25
∙
Lehdistötiedote
DNB Carnegie Access: Karolinska Development: Aims to strengthen its balance shee
1 joulu 08.49
∙
Markkinakommentti
BÖRSEN: NED MED OMVÄRLDEN, BANKER MOT STRÖMMEN, OMXS30 -0,2%
1 joulu 08.33
∙
Osakeuutinen
Stockholm Bullets - VEF stiger efter största innehavet Creditas satt omsättningsrekord
1 joulu 07.35
∙
Markkinakommentti
BÖRSEN: VÄNTAS ÖPPNA NEDÅT I LINJE MED OMVÄRLDEN
1 joulu 07.13
∙
Osakeuutinen
Karolinska Development föreslår nyemission på 203 miljoner kronor samt namnbyte
1 joulu 07.03
∙
Osakeuutinen
KAROLINSKA DEVELOPMENT: FÖRETRÄDESEMISSION 203 MLN KR
1 joulu 07.00
∙
Lehdistötiedote
Karolinska Development AB (publ) announces a rights issue of up to approximately SEK 203 million, subject to subsequent approval by the Extraordinary General Meeting, and proposes change of company name to KDventures AB
1 joulu 07.00
∙
Lehdistötiedote
Karolinska Development AB (publ) offentliggör företrädesemission om upp till cirka 203 MSEK, villkorat av bolagsstämmans efterföljande godkännande samt föreslår namnbyte till KDventures AB
17 marras 14.14
∙
Osakeuutinen
DNB Carnegie sänker motiverat värde på Karolinska Development till 1,4-2,1 kronor per aktie
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Näytä kaikki
Seuraava tapahtuma
2025 Q4 -tulosraportti
13.2.2026
Menneet tapahtumat
2025 Q3 -tulosraportti
14.11.
2025 Q2 -tulosraportti
29.8.
2025 Q1 -tulosraportti
30.4.
2024 Q4 -tulosraportti
14.2.
2024 Q3 -tulosraportti
15.11.2024
Datan lähde: FactSet, Quartr
Tuotteita joiden kohde-etuutena tämä arvopaperi
Sertifikaatit
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
An (1) existing share (regardless of share class) entitles to five (5) subscription rights and two (2) subscription rights give the right to subscribe for one (1) new share of series B.
Updated assessment of Net Asset Value in Karolinska Development
The official NAV discount at a price of 0.335 SEK is approx. 92 % (ibindex.se). After a fully subscribed issue, it will fall to approx. 77 % at an expected price of 0.30 SEK.
(Briefly, the price can of course be lower right after the issue, as is unfortunately often seen when the guarantors sell off the new shares they have bought at a large discount compared to us other shareholders.)
I am, however, more interested in what I call the real NAV discount.
I assume that the share price is 0.30 SEK, that the issue is fully subscribed and adds 203 million SEK minus 17 million SEK in costs.
Under these assumptions, the buyers of the newly issued shares get the entire holding of unlisted shares quite free – or almost free. More precisely, the real NAV discount under these assumptions becomes 99 %.
I calculate the real NAV discount solely in relation to the unlisted shares, by first fully offsetting the value of the listed shares (there is only a very small listed share left currently) as well as positive capital including receivables (and offsets any debt.)
After that, it is of course necessary to look at what unlisted shares are in the company's portfolio.
Firstly, one must consider whether the value of the unlisted shares is correctly determined. I do not have the prerequisites to know that, and must therefore assess whether I find the management trustworthy and competent, including to what extent the management itself invests, and whether there are larger investors who sometimes supplement further.
But now that the entire pool of unlisted shares is free, much uncertainty can be priced in.
Secondly, one must consider the security in relation to how much individual shares make up in the portfolio. In this share, Umecrine alone accounts for almost 55 % of the unlisted shares, which some believe is the reason for the large NAV discount in this company. But the large NAV discount more than sufficiently accounts for if Umecrine, contrary to expectations, should be worth 0 kr. So that does not worry me. Even if all 3 largest companies were to go bankrupt, the share's NAV would still be intact in relation to the price.
I choose, as I usually do with this type of issue, to sell all shares (almost) in the company, even if it is loss-making, and use the money to buy new ones in the issue. This way I support the issue and contribute to fewer shares being sold to guarantors with further discount and dilution of other shareholders.
KDEV is absolutely ridiculously priced at the moment. It trades at half the tax value of the accumulated losses. In other words, a profitable buyer who can utilize the losses will get all other net assets for free plus a good deal on top.
They exist partly as Invox Pharma and partly as Worldwide International Investments. I think it's the same owner behind them. Does anyone have other information?
Is there any possibility that the General Meeting of Shareholders will reject this very dilutive share issue? We will soon be trading below the issue price!
Yes, why doesn't the main owner make a commitment corresponding to their share? They dominate the board, so it's surely not a question of the issue not being anchored with the largest owner? Is it 1. because they don't want/can't invest another 100M here and the market will soon be flooded with subscription rights, or is it 2. because they want to invest even more and hope for a low subscription rate so they can increase their stake at a cheap price? Should that then trigger a mandatory bid? If it's alternative 1, then there's surely the possibility that a new larger owner will come in who can take over power and carry out a slaughter and carve-out process to extract the net asset value?
Very relevant consideration. Unfortunately, I have the same thoughts both here and especially in First Ventures' emission. In that light, I see no other option than to participate in the emission.
Ner, ner, ner, ner..new issue, after new issue and the poor small shareholders lose and lose......
Näytä enemmän
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
3 500
0,313
Myynti
Määrä
0,318
74 797
Viimeisimmät kaupat
Näytä enemmän
Aika
Hinta
Määrä
Ostaja
Myyjä
0,317
9 560
-
-
0,317
38 292
-
-
0,317
1 487
-
-
0,318
8 490
-
-
0,318
112 343
-
-
Ylin
0,337
VWAP
0,317
Alin
0,312
VaihtoMäärä
0,6 1 981 303
VWAP
0,317
Ylin
0,337
Alin
0,312
VaihtoMäärä
0,6 1 981 303
Tietoa osakekaupankäyntiin liittyvistä riskeistä
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.